Literature DB >> 20034430

A mouse surgical model for metastatic ovarian granulosa cell tumor.

Marie-Eve Nadeau1, M Johanna Kaartinen, Marie-Noëlle Laguë, Marilène Paquet, Louis M Huneault, Derek Boerboom.   

Abstract

We recently described a genetically engineered mouse model that develops ovarian granulosa cell tumors (GCTs) that mimic many aspects of the advanced human disease, including distant dissemination. However, because the primary tumors killed their hosts before metastases were able to form, the use of these mice to study metastatic disease required the development of a simple, reliable, and humane surgical protocol for the excision of large GCTs from debilitated mice. Here we describe a protocol involving multimodal anesthesia, tumor removal through ventral midline celiotomy and perioperative fluid therapy, and analgesia that led to the postoperative survival of more than 90% of mice, despite the removal of tumors representing as much as 10% of the animal's body weight. Intraabdominal recurrence of the GCT did not occur in surviving animals, but most developed pulmonary or adrenal metastases (or both) by 12 wk after surgery. We propose that this mouse model of metastatic GCT will serve as a useful preclinical model for the development of novel treatment modalities and diagnostic techniques. Furthermore, our results delineate anesthetic and surgical principles for the removal of large abdominal tumors from mice that will be applicable to other models of human cancers.

Entities:  

Mesh:

Year:  2009        PMID: 20034430      PMCID: PMC2798836     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  7 in total

1.  Granulosa cell tumour: a recurrence 40 years after initial diagnosis.

Authors:  Nathalie East; Abdulaziz Alobaid; Frédéric Goffin; Karim Ouallouche; Philippe Gauthier
Journal:  J Obstet Gynaecol Can       Date:  2005-04

Review 2.  Ferret, rabbit, and rodent anesthesia.

Authors:  S L Cantwell
Journal:  Vet Clin North Am Exot Anim Pract       Date:  2001-01

3.  Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.

Authors:  Alexandre Boyer; Marilène Paquet; Marie-Noëlle Laguë; Louis Hermo; Derek Boerboom
Journal:  Carcinogenesis       Date:  2009-02-23       Impact factor: 4.944

4.  Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression.

Authors:  Marie-Noëlle Laguë; Marilène Paquet; Heng-Yu Fan; M Johanna Kaartinen; Simon Chu; Soazik P Jamin; Richard R Behringer; Peter J Fuller; Andrew Mitchell; Monique Doré; Louis M Huneault; Joanne S Richards; Derek Boerboom
Journal:  Carcinogenesis       Date:  2008-08-06       Impact factor: 4.944

Review 5.  Granulosa cell tumor of the ovary.

Authors:  Susan Tinsley Schumer; Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

6.  Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary.

Authors:  Jeannine Villella; Francois R Herrmann; Sadhana Kaul; Shashikant Lele; David Marchetti; Joan Natiella; Kunle Odunsi; Paulette Mhawech-Fauceglia
Journal:  Int J Gynecol Pathol       Date:  2007-04       Impact factor: 2.762

Review 7.  Animal models of ovarian cancer.

Authors:  Barbara C Vanderhyden; Tanya J Shaw; Jean-François Ethier
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

  7 in total
  2 in total

1.  Anti-VEGFA Therapy Reduces Tumor Growth and Extends Survival in a Murine Model of Ovarian Granulosa Cell Tumor.

Authors:  Mayra Tsoi; Marie-Noëlle Laguë; Alexandre Boyer; Marilène Paquet; Marie-Ève Nadeau; Derek Boerboom
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

2.  First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.

Authors:  Oystein Helland; Mihaela Popa; Olav K Vintermyr; Anders Molven; Bjørn Tore Gjertsen; Line Bjørge; Emmet McCormack
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.